Ilaria Pola

1 month ago | alz-journals.onlinelibrary.wiley.com | Nicholas Ashton |Andrea L. Benedet |Guglielmo Di Molfetta |Ilaria Pola

1 BACKGROUND Discovery plasma proteomics has long since demonstrated a differential signal in the blood of patients clinically diagnosed with Alzheimer's disease (AD).1, 2 These earlier studies used agnostic methods to discover novel biomarkers—proteomic technologies not predicated on any a priori hypotheses in a case-control approach1, 3-6 but later evolved to an endophenotype design based on pathology; brain atrophy measures,1, 7-9 cerebrospinal fluid (CSF) biomarkers,10 or amyloid beta...

2 months ago | alz-journals.onlinelibrary.wiley.com | Ilaria Pola |Nicholas Ashton |Wagner S. Brum |Nesrine Rahmouni

1 BACKGROUND Alzheimer's disease (AD) is a progressive pathophysiological process characterized by the accumulation of amyloid-β (Aβ) and tau proteins, ultimately leading to neurodegeneration and cognitive decline.1, 2 In this context, neuroinflammation has been suggested as a significant contributor to AD progression.3, 4 Studies in mouse models of Aβ and tau suggest that microglial reactivity may accelerate Aβ plaque deposition and tau spreading, with immune-related alterations observed in...

Jul 29, 2024 | medrxiv.org | Nicholas Ashton |Andrea L. Benedet |Ilaria Pola |Guglielmo Di Molfetta

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon,...

Mar 11, 2024 | thelancet.com | Joseph Therriault |Nicholas Ashton |Ilaria Pola

SummaryBlood-based biomarkers of Alzheimer’s disease (AD) have become increasingly important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 is the most promising due to its excellent sensitivity and specificity for AD-related pathological changes. We compared the performance of two commercially available plasma p-tau217 assays (ALZpath p-tau217 and Janssen p-tau217+) in 294 individuals cross-sectionally.